David L. Gibbs - Concepedia

Author

David L. Gibbs

Also Known As

Baric, Ralph S., D Gibbs, D L Gibbs, D. Gibbs, D. L. GIBBS, D. L. Gibbs, D.L Gibbs, DL Gibbs, David Gibbs, David L Gibbs

152

Publications

13.4K

Citations

H-Index

116

Concepts

All Affiliations

Institute for Systems Biology University of Iowa University of California, San Francisco University of North Carolina at Chapel Hill Women's and Children's Hospital

About

David L. Gibbs is an author at Institute for Systems Biology specializing in medicine, microbiology, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2.1K
2	Health Sciences	8	8	1.4K
3	Engineering	5	5	127
4	Public Health	2	2	106
5	Biology	1	1	15

David L. Gibbs

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
The Immune Landscape of Cancer Vésteinn Thórsson, David L. Gibbs, Scott D. Brown, Immunity	2018	6K
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of <i>Candida</i> Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs, Journal of Clinical Microbiology Fluconazole-r IsolatesAntifungal AgentAntimicrobial SusceptibilityHealth SciencesFungal Pathogen	2010	693
Integrative Molecular Characterization of Malignant Pleural Mesothelioma Julija Hmeljak, Francisco Sánchez-Vega, Katherine A. Hoadley, Cancer Discovery	2018	585
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics Li Ding, Matthew H. Bailey, Eduard Porta‐Pardo, Cell	2018	425
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs, Journal of Clinical Microbiology	2008	367
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of <i>Candida</i> Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs, Journal of Clinical Microbiology	2007	282
<i>Candida krusei</i> , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs, Journal of Clinical Microbiology Candida KruseiAntifungal AgentHealth SciencesMicrobial PathogensTemporal Trends	2007	249
Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof <i>Candida</i> and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing Michael A. Pfaller, Daniel J. Diekema, Michael G. Rinaldi, Journal of Clinical Microbiology	2005	222
<i>Candida guilliermondii</i> , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program Michael A. Pfaller, Daniel J. Diekema, M. Méndez, Journal of Clinical Microbiology	2006	188
A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion L D Liebowitz, H. R. Ashbee, E. G. V. Evans, Diagnostic Microbiology and Infectious Disease Antifungal AgentHealth SciencesDisk DiffusionCandida SpeciesYear Global Evaluation	2001	175

Page 1